Drugs / BLU-808
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT06948032 | Aug 2024 → Jan 2025 | — | Blueprint Medicines Corporation | Completed | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT06931405 | May 2025 → Dec 2026 expected | chronic inducible urticaria | Blueprint Medicines Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT06922448 | Apr → Sep 2025 | allergic disease | Blueprint Medicines Corporation | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-02-28 | Blueprint Medicines Corporation | Results Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress blueprintmedicines.com ↗
BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor |
| 2025-01-12 | Blueprint Medicines Corporation | Results Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth blueprintmedicines.com ↗
BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained tryptase reductions exceeding 80% in Phase 1 healthy volunteer study |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-02-28 | Blueprint Medicines Corporation | Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress blueprintmedicines.com ↗ |
| 2025-01-12 | Blueprint Medicines Corporation | Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth blueprintmedicines.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLU-808 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06931405 ↗ |
| Action | Inhibit | “Wild-type KIT Inhibitor” NCT06922448 ↗ |
| Route | Oral | “BLU-808 will be administered orally for 28 days.” NCT06922448 ↗ |
| Target | KIT | “Wild-type KIT Inhibitor” NCT06922448 ↗ |